Alzheimer's disease-associated mutations increase amyloid precursor protein resistance to γ-secretase cleavage and the Aβ42/Aβ40 ratio

Cell Discovery

Volumn 2, Issue , 2016, Pages

  Xu, Ting Hai ^a,b,c   Yan, Yan ^a,b,c   Kang, Yanyong ^b   Jiang, Yi ^a   Melcher, Karsten ^b   Xu, H Eric ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Alzheimer's disease; C99; epsilon cleavage assay; familial Alzheimer disease (FAD) linked mutations; secretase

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE; NOTCH RECEPTOR;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; EPSILON CLEAVAGE ASSAY; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR PATHOLOGY; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN FAMILY; PROTEIN INTERACTION ASSAY; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN SECRETION; REPORTER GENE; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; TANGO ASSAY; UPREGULATION; WESTERN BLOTTING;

EID: 85028641966     PISSN: None     EISSN: 20565968     Source Type: Journal    
DOI: 10.1038/celldisc.2016.26     Document Type: Article

References (55)

1. Burns A, Iliffe S. Alzheimer's disease. Br Med J 2009; 338: b158.
2. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain 2011; 4: 3.
3. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Sub-cell Biochem 2012; 65: 329-352.
4. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1: a006189.
5. Chow VW, Mattson MP, Wong PC, Gleichmann M. An overview of APP processing enzymes and products. Neuromol Med 2010; 12: 1-12.
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
7. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 2009; 41: 1261-1268.
8. Harrington CR. The molecular pathology of Alzheimer's disease. Neuroimaging Clin N Am 2012; 22: 11-22, vii.
9. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487-498.
10. De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010; 6: 99-107.
11. Fraering PC, Ye W, Strub JM et al. Purification and characterization of the human gamma-secretase complex. Biochemistry 2004; 43: 9774-9789.
12. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA 2003; 100: 6382-6387.
13. Dang S, Wu S, Wang J et al. Cleavage of amyloid precursor protein by an archaeal presenilin homologue PSH. Proc Natl Acad Sci USA 2015; 112: 3344-3349.
14. LaVoie MJ, Fraering PC, Ostaszewski BL et al. Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. J Biol Chem 2003; 278: 37213-37222.
15. Li Y, Lu SH, Tsai CJ et al. Structural interactions between inhibitor and substrate docking sites give insight into mechanisms of human PS1 complexes. Structure 2014; 22: 125-135.
16. De Strooper B, Annaert W, Cupers P et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398: 518-522.
17. Steiner H, Duff K, Capell A et al. A loss of function mutation of presenilin-2 interferes with amyloid betapeptide production and notch signaling. J Biol Chem 1999; 274: 28669-28673.
18. Shen J, Kelleher RJ 3rd. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 2007; 104: 403-409.
19. De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. Embo Rep 2007; 8: 141-146.
20. Lu P, Bai XC, Ma D et al. Three-dimensional structure of human gamma-secretase. Nature 2014; 512: 166-170.
21. Sun L, Zhao L, Yang G et al. Structural basis of human gamma-secretase assembly. Proc Natl Acad Sci USA 2015; 112: 6003-6008.
22. Bai XC, Yan C, Yang G et al. An atomic structure of human gamma-secretase. Nature 2015; 525: 212-217.
23. Barnea G, Strapps W, Herrada G et al. The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci USA 2008; 105: 64-69.
24. Zhang C, Khandelwal PJ, Chakraborty R et al. An AICD-based functional screen to identify APP metabolism regulators. Mol Neurodegener 2007; 2: 15.
25. Karlstrom H, Bergman A, Lendahl U, Naslund J, Lundkvist J. A sensitive and quantitative assay for measuring cleavage of presenilin substrates. J Biol Chem 2002; 277: 6763-6766.
26. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. Exploring the sequence space for tetracycline dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000; 97: 7963-7968.
27. Kang Y, Zhou XE, Gao X et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature 2015; 523: 561-567.
28. Wong GT, Manfra D, Poulet FM et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-12882.
29. Dovey HF, John V, Anderson JP et al. Functional gammasecretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76: 173-181.
30. Mitani Y, Yarimizu J, Saita K et al. Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 2012; 32: 2037-2050.
31. Luistro L, He W, Smith M et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009; 69: 7672-7680.
32. Cook JJ, Wildsmith KR, Gilberto DB et al. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci 2010; 30: 6743-6750.
33. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPRCas9 system. Nat Protoc 2013; 8: 2281-2308.
34. Zheng Q, Cai X, Tan MH et al. Precise gene deletion and replacement using the CRISPR/Cas9 system in human cells. Biotechniques 2014; 57: 115-124.
35. Doody RS, Raman R, Farlow M et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013; 369: 341-350.
36. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord 2013; 6: 19-33.
37. Zhao G, Mao G, Tan J et al. Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. J Biol Chem 2004; 279: 50647-50650.
38. Olsson F, Schmidt S, Althoff V et al. Characterization of intermediate steps in amyloid beta (Abeta) production under near-native conditions. J Biol Chem 2014; 289: 1540-1550.
39. Zhao G, Tan J, Mao G, Cui MZ, Xu X. The same gamma-secretase accounts for the multiple intramembrane cleavages of APP. J Neurochem 2007; 100: 1234-1246.
40. Xu X. Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. J Alzheimers Dis 2009; 16: 211-224.
41. Zhao G, Cui MZ, Mao G et al. Gamma-cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. J Biol Chem 2005; 280: 37689-37697.
42. Takami M, Nagashima Y, Sano Y et al. Gamma-secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 2009; 29: 13042-13052.
43. Pauwels K, Williams TL, Morris KL et al. Structural basis for increased toxicity of pathological abeta42:abeta40 ratios in Alzheimer disease. J Biol Chem 2012; 287: 5650-5660.
44. Suarez-Calvet M, Belbin O, Pera M et al. Autosomaldominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Abeta production. J Neurochem 2014; 128: 330-339.
45. Chen W, Gamache E, Rosenman DJ et al. Familial Alzheimer's mutations within APPTM increase Abeta42 production by enhancing accessibility of epsiloncleavage site. Nat Commun 2014; 5: 3037.
46. Barrett PJ, Song Y, Van Horn WD et al. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 2012; 336: 1168-1171.
47. Beel AJ, Sanders CR. Substrate specificity of gammasecretase and other intramembrane proteases. Cell Mol Life Sci 2008; 65: 1311-1334.
48. Haapasalo A, Kovacs DM. The many substrates of presenilin/gamma-secretase. J Alzheimers Dis 2011; 25: 3-28.
49. Uemura K, Kihara T, Kuzuya A et al. Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. Neurosci Lett 2006; 402: 278-283.
50. Hecimovic S, Wang J, Dolios G, Martinez M, Wang R, Goate AM. Mutations in APP have independent effects on Abeta and CTFgamma generation. Neurobiol Dis 2004; 17: 205-218.
51. Lichtenthaler SF, Wang R, Grimm H, Uljon SN, Masters CL, Beyreuther K. Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc Natl Acad Sci USA 1999; 96: 3053-3058.
52. Annaert WG, Esselens C, Baert V et al. Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron 2001; 32: 579-589.
53. Dimitrov M, Alattia JR, Lemmin T et al. Alzheimer's disease mutations in APP but not gamma-secretase modulators affect epsilon-cleavage-dependent AICD production. Nat Commun 2013; 4: 2246.
54. Bolduc DM, Montagna DR, Gu Y, Selkoe DJ, Wolfe MS. Nicastrin functions to sterically hinder gamma-secretasesubstrate interactions driven by substrate transmembrane domain. Proc Natl Acad Sci USA 2016; 113: E509-E518.
55. Buchan DW, Minneci F, Nugent TC, Bryson K, Jones DT. Scalable web services for the PSIPRED Protein Analysis Workbench. Nucleic Acids Res 2013; 41: W349-W357.